A comprehensive view of POINT Biopharma Global Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly completes acquisition of POINT Biopharma; POINT has a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer
Published: December 27, 2023 by Eli Lilly & Co.
Eli Lilly extends tender offer expiration for acquisition of all issued and outstanding shares of POINT Biopharma Global until Dec. 22; the offer price is US$12.50 per share in cash
Published: December 18, 2023 by Eli Lilly & Co.
Eli Lilly extends expiration of tender offer to acquire Point Biopharma until Dec. 15, 2023 for $12.50 per share
Published: December 04, 2023 by Eli Lilly & Co.
Eli Lilly to acquire POINT Biopharma Global, a radiopharmaceutical firm with several clinical and preclinical-stage cancer treatments in development, in a deal worth approximately US$1.4B
Published: October 03, 2023 by Eli Lilly & Co.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count